Schr�dinger (Nasdaq: SDGR), whose physics-based computational
platform is transforming the way therapeutics and materials are
discovered, today announced that new data on SGR-1505, its
investigational MALT1 inhibitor, and SGR-2921, its investigational
CDC7 inhibitor, will be presented during a poster session at the
American Society of Hematology (ASH) 65th Annual Meeting taking
place virtually and in San Diego, California, December 9-12,
2023.
Presentation of SGR-1505 data will include further
characterization in preclinical oncology models as well as
preliminary clinical biomarker information from the Phase 1 study
in healthy subjects, which is nearing completion. The data support
continued development of SGR-1505 as a potential therapy for
patients with advanced B-cell malignancies, and a Phase 1
dose-escalation study in this patient population is ongoing.
Additionally, data will be presented for SGR-2921 demonstrating
strong anti-leukemic activity in preclinical models of acute
myeloid leukemia (AML) representing difficult-to-treat disease.
CDC7 is a cell cycle kinase in the DNA damage-response pathway and
has emerged as a promising therapeutic target in oncology,
including for the treatment of AML. Schr�dinger recently initiated
a Phase 1 dose-escalation study of SGR-2921 designed to evaluate
the safety, pharmacokinetics, pharmacodynamics, and recommended
dose of SGR-2921 in patients with AML or myelodysplastic
syndrome.
Details of the data presentations are as follows:
Title: SGR-1505 Is a Potent MALT1 Protease Inhibitor with a
Potential Best-in-Class Profile Abstract number: 2997 Date &
time: Sunday, December 10, 6:00 p.m. - 8:00 p.m. PDT Location: San
Diego Convention Center, Halls G-H
Title: SGR-2921, a Potent CDC7 Inhibitor, Demonstrates
Significant Anti-Leukemic Responses in Patient-Derived AML Models
Representing Difficult-to-Treat Disease Abstract number: 2801 Date
& time: Sunday, December 10, 6:00 p.m. - 8:00 p.m. PDT
Location: San Diego Convention Center, Halls G-H
Additionally, the following clinical trial-in–progress posters
will be presented for both SGR-1505 and SGR-2921:
Title: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study
of SGR-1505 As Monotherapy in Subjects with Mature B-Cell
Malignancies Abstract number: 3102 Date & time: Sunday,
December 10, 6:00 p.m. - 8:00 p.m. PDT Location: San Diego
Convention Center, Halls G-H
Title: A First-in-Human, Phase 1, Dose Escalation Study of
SGR-2921 As Monotherapy in Subjects with Relapsed/Refractory Acute
Myeloid Leukemia or Myelodysplastic Syndrome Abstract number: 1548
Date & time: Saturday, December 9, 5:30 P.M. - 7:30 P.M. PDT
Location: San Diego Convention Center, Halls G-H
Schr�dinger will review these data as part of its Pipeline Day,
taking place virtually and in person on December 14, 2023. The
company’s Pipeline Day will be a hybrid event, with limited
in-person attendance available to members of the investment
community, and a simultaneous webcast will be available for
individual investors and other interested parties who wish to join
virtually. The live presentation can be accessed in the “Investors”
section of Schr�dinger’s website and will be archived for
approximately 90 days. To participate in the live webcast, please
register for the event here. It is recommended that participants
register at least 15 minutes in advance of the event.
About Schr�dinger
Schr�dinger is transforming the way therapeutics and materials
are discovered. Schr�dinger has pioneered a physics-based
computational platform that enables discovery of high-quality,
novel molecules for drug development and materials applications
more rapidly and at lower cost compared to traditional methods. The
software platform is licensed by biopharmaceutical and industrial
companies, academic institutions, and government laboratories
around the world. Schr�dinger’s multidisciplinary drug discovery
team also leverages the software platform to advance a portfolio of
collaborative and proprietary programs to address unmet medical
needs.
Founded in 1990, Schr�dinger has approximately 800 employees and
is engaged with customers and collaborators in more than 70
countries. To learn more, visit www.schrodinger.com, follow us on
LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995
including, but not limited to those statements regarding the
potential advantages of Schr�dinger’s computational platform, the
clinical potential and favorable properties of its product
candidates, including SGR-1505 and SGR-2921, the potential for
SGR-1505 to be used for the treatment of advanced B-cell
malignancies, the potential for SGR-2921 to be used for the
treatment of AML or myelodysplastic syndrome, and the timing,
progress, and results of clinical trials for its product
candidates. Statements including words such as “aim,” “anticipate,”
“believe,” “contemplate,” “continue,” “could,” “estimate,”
“expect,” “goal,” “intend,” “may,” “might,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
statements in the future tense are forward-looking statements.
These forward-looking statements reflect Schr�dinger’s current
views about its plans, intentions, expectations, strategies and
prospects, which are based on the information currently available
to the company and on assumptions the company has made. Actual
results may differ materially from those described in these
forward-looking statements and are subject to a variety of
assumptions, uncertainties, risks and important factors that are
beyond Schr�dinger’s control, including the uncertainties inherent
in drug development and commercialization, such as the conduct of
research activities and the timing of and its ability to initiate
and complete preclinical studies and clinical trials, whether
results from preclinical studies will be predictive of the results
of later preclinical studies and clinical trials, uncertainties
associated with the regulatory review of clinical trials and
applications for marketing approvals and the ability to retain and
hire key personnel on its business and other risks detailed under
the caption “Risk Factors” and elsewhere in the company’s
Securities and Exchange Commission filings and reports, including
its Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2023, filed with the Securities and Exchange
Commission on November 1, 2023, as well as future filings and
reports by the company. Any forward-looking statements contained in
this press release speak only as of the date hereof. Except as
required by law, Schr�dinger undertakes no duty or obligation to
update any forward-looking statements contained in this press
release as a result of new information, future events, changes in
expectations or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102362587/en/
Matthew Luchini (Investors) Schr�dinger, Inc.
matthew.luchini@schrodinger.com 917-719-0636
Allie Nicodemo (Media) Schr�dinger, Inc.
allie.nicodemo@schrodinger.com 617-356-2325
Schrodinger (NASDAQ:SDGR)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Schrodinger (NASDAQ:SDGR)
Historical Stock Chart
Von Mai 2023 bis Mai 2024